Tissue Repair logo

Tissue Repair(ASX) TRP

Market CapA$5.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-88%
5 YearN/A
1 Year-69%
1 Month+6%
A$0.09
+0.00%
+0.00Today
Tissue Repair last closing stock price
MetricPriceDate
Last closeAUD 0.092026-10-08
Tissue Repair stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.092026-10-01
1 month+6.25%AUD 0.082026-09-07
3 month-22.73%AUD 0.112026-07-08
Year to date-77.92%AUD 0.392025-12-30
1 year-69.09%AUD 0.282025-10-08
3 year-69.09%AUD 0.282023-10-06
Since inception-87.77%AUD 0.702021-11-18

Tissue Repair Financials at a Glance

Market Cap

A$5.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.19M

Net Income (TTM)

-A$9.60M

EPS (TTM)

-A$0.09

P/E Ratio

-0.96

Dividend

A$0.00

Beta (Volatility)

0.16 (Low)

Price

A$0.09

Volume

0

Open

A$0.09

Previous Close

A$0.09

Daily Range

A$0.09 - A$0.09

52-Week Range

A$0.06 - A$0.48

Estimated Earnings Date

Mar 4, 2027

TRP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tissue Repair

Tissue Repair Ltd is an Australian clinical-stage biopharmaceutical firm focused on innovative solutions for wound care. The company specializes in developing treatments for chronic wounds and recovery after cosmetic procedures, with a robust product pipeline aimed at addressing complex dermal injuries.

Products and Services
  • TR-987 for chronic wound treatment
  • Innovative dressings and matrices utilizing proprietary Glucoprime technology
  • TR Pro+ for post-procedure care in aesthetic treatments
Growth Outlook
  • Strong focus on chronic wound care market projected to grow significantly
  • Expansion into animal health and novel therapeutic areas underway
  • Innovative product pipeline expected to drive future revenue growth
Financial Highlights
  • Recent quarterly revenue of AUD 253,882, showing potential for growth
  • Cash and cash equivalents of AUD 4.77 million, providing operational stability
  • Current ratio of 6.36 indicates strong liquidity position
Tissue Repair Ltd operates in the biotechnology sector, emphasizing advanced wound care solutions. The company’s innovative products, such as TR-987 and TR Pro+, are designed to meet the growing demand for effective treatments in chronic wound management and post-cosmetic procedure recovery. The focus on proprietary technologies like Glucoprime positions the company favorably within a competitive market. The growth outlook for Tissue Repair is promising, driven by the increasing prevalence of chronic wounds and the expansion into new therapeutic areas, including animal health. The company’s strategic initiatives aim to leverage its innovative product pipeline to capture market share and enhance revenue streams. Financially, Tissue Repair Ltd has demonstrated resilience with a recent quarterly revenue of AUD 253,882, reflecting the potential for future growth. The company maintains a solid liquidity position, with cash and cash equivalents totaling AUD 4.77 million, ensuring operational stability. A current ratio of 6.36 further underscores the company’s ability to meet short-term obligations, providing a strong foundation for future development and expansion.
AI Generated • Sep 22, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Tony Charara

Website

www.tissuerepair.com.au

Headquarters

Chatswood, NSW 2067, AU

TRP Financials

Key Financial Metrics (TTM)

Gross Margin

-172.86%

Operating Margin

-1425.03%

Net Income Margin

-958.01%

Return on Equity

-52.04%

Return on Capital

-90.89%

Return on Assets

-51.84%

Earnings Yield

-1.04%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$5.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

60.46M

Volume

0

Avg. Volume

92.27K

Financials (TTM)

Gross Profit

A$1.67M

Operating Income

-A$12.70M

EBITDA

-A$12.59M

Operating Cash Flow

-A$10.65M

Capital Expenditure

-A$442.25K

Free Cash Flow

-A$11.09M

Cash & ST Invst.

A$4.77M

Total Debt

A$0.00

Tissue Repair Performance Analysis

Tissue Repair annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 3,076N/A
20242024-06-30AUD 152,2404849.3%
20252025-06-30AUD 423,320178.1%
20262026-06-30AUD 559,70232.2%
Tissue Repair sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-62.2%
Q42025-06-30202.4%
Q22025-12-31-84.5%
Q42026-06-30-17.0%
Tissue Repair annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.07-39.0%
20242024-06-30AUD -0.07-0.9%
20252025-06-30AUD -0.072.5%
20262026-06-30AUD -0.0926.5%
Tissue Repair sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-36.3%
Q42025-06-3034.7%
Q22025-12-31-29.6%
Q42026-06-30-46.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$253.88K

-85.3%

Gross Profit

-A$967.51K

-156.0%

Gross Margin

-3.81%

N/A

Market Cap

A$5.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.03M

N/A

Employees

5

N/A

Net Income

-A$3.19M

-69.5%

EBITDA

-A$4.59M

-95.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$4.77M

-71.0%

Total Debt

A$0.00

N/A

Accounts Receivable

A$4.20M

+66.0%

Inventory

A$737.75K

+243.6%

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-51.84%

N/A

Return on Invested Capital

-90.81%

N/A

Free Cash Flow

-A$4.03M

-100.6%

Operating Cash Flow

-A$4.01M

-99.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PAB.AXPatrys Limited
A$0.03-6.25%
IMC.AXImmuron Limited
A$0.05+0.00%
NTI.AXNeurotech International Limited
A$0.01-7.14%
AT1.AXAtomo Diagnostics Limited
A$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About TRP

What is the current price of Tissue Repair?

Tissue Repair is trading at A$0.09 per share.

What is the 52-week range for Tissue Repair?

Over the past 52 weeks, Tissue Repair has traded between A$0.06 and A$0.48.

How much debt does Tissue Repair have?

As of the most recent reporting period, Tissue Repair reported total debt of A$0.00.

How much cash does Tissue Repair have on hand?

Tissue Repair reported A$4.77M in cash and cash equivalents in its most recent financial results.

What is Tissue Repair’s dividend yield?

Tissue Repair does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services